Keyphrases
Breast Cancer
100%
Tumor-infiltrating Lymphocytes
100%
Oncology Biomarkers
100%
Immuno-oncology
100%
Programmed Death-ligand 1 (PD-L1)
33%
Immune Checkpoint Inhibitors
33%
Lymphocytes
16%
Immunogenic
16%
Oncology
16%
Clinical Utility
16%
Infiltration
16%
Clinical Utilization
16%
Improved Survival
16%
Women with Breast Cancer
16%
Low-middle Income Countries
16%
Clinical Work
16%
Patients with Breast Cancer
16%
Triple-negative Breast Cancer
16%
Prognostic Biomarker
16%
Cytotoxic Therapy
16%
Clinical Validity
16%
Patient Advocate
16%
Signaling Axis
16%
Programmed death-1/programmed Death-ligand 1
16%
Analytical Validity
16%
Predictive Biomarker
16%
Medicine and Dentistry
Oncology
100%
Immunoglobulin
100%
Biological Marker
100%
Breast Cancer
100%
Tumor Infiltrating Lymphocyte
100%
Programmed Death 1 Ligand 1
50%
Immune Checkpoint Inhibitor
33%
Malignant Neoplasm
16%
Immunotherapy
16%
Lymphocyte
16%
Triple Negative Breast Cancer
16%
Patient Advocate
16%
Immunology and Microbiology
Intravenous Immunoglobulin
100%
Tumor-Infiltrating Lymphocytes
100%
Programmed Death 1 Ligand 1
50%
Lymphocyte
16%
Immunotherapy
16%
Prognostic Biomarker
16%